Reflux in Medical Technology

Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment

... for the minimally invasive treatment of venous reflux disease , announced today that the Journal of ... saphenous vein, the most common site of venous reflux in the leg. The RECOVERY trial was a multicenter, ... premier technology for the treatment of venous reflux disease, a medical condition afflicting millions ...

American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought

... who do not exhibit symptoms associated with acid reflux such as heartburn or stomach pain. Patients ... "Now we know with confidence that silent acid reflux does not play a significant role in poor asthma ... For asthma patients with symptoms of gastric reflux such as heartburn that occurs at least twice ...

Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment

... minimally invasive treatment of gastroesophageal reflux disease (GERD) has commenced a pivotal clinical trial of its LINX(TM) reflux Management System. The trial, which is being ... the esophagus. When defective, it allows abnormal reflux of stomach acids and bile into the esophagus. ...

NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology

... for the minimally invasive treatment of venous reflux disease , today announced that the UK NHS ... is the preferred technique to treat venous reflux because it requires no special modifications to ... pressure in the legs as a result of venous reflux and faulty valves in the leg veins. Left ...

FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents

... (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in patients ages 12-16. Further, ... heartburn and other symptoms associated with acid reflux disease. ACIPHEX is also used in adults for the ... (erosive) acid reflux disease (gastroesophageal reflux disease). Important Safety Information ...

EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study

... surgical management of gastroesophageal reflux disease (GERD) patients. Dr. John Hunter, ... are demanding a permanent solution for their reflux disease in the face of failing pharmacological ... diseases, including gastroesophageal reflux disease (GERD) and other GI conditions. EsophyX ...

Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium

... the minimally invasive treatment of venous reflux disease, announced that interim results from two ... is the best choice for the treatment of venous reflux disease for the millions of varicose vein ... for the minimally invasive treatment of venous reflux disease, a progressive condition that causes the ...

Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms

... -- The link between gastroesophageal reflux disease (GERD) and obesity has long ... Resolution in Patients with Gastroesophageal reflux Disease (GERD) 2007 ACG Presidential Poster ... in Patients with Gastroesophageal reflux Disease (GERD). The American College of ...

Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease

... developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other ... to clear the bolus, appears to precipitate reflux symptoms. Despite adequate control of ... of the esophagus to acidic and weakly acidic reflux and this may improve the symptoms of GERD. About ...

DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux

... gel), for the treatment of vesicoureteral reflux (VUR) in children, reduced the incidence of ... DEFLUX. Success was defined as the resolution of reflux on a three-month postoperative VCUG. All patients ... for antibiotic resistance. About Vesicoureteral reflux (VUR) Approximately one percent of all children ...

Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development

... this disease." As a result of chronic injury from gastroesophageal reflux disease (GERD), the normal esophageal lining is replaced with abnormal ... the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a ...

Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed

... Sunday, October 5 -- TAK-390MR Maintains Relief of Gastroesophageal reflux Disease (GERD) Symptoms and Improvements in Quality of Life in GERD ... on the stomach. GERD is a chronic condition commonly known as acid reflux disease. GERD can occur when the valve at the lower end of the esophagus, ...

Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective

... leader in medical devices for the minimally invasive treatment of venous reflux disease, today presented positive clinical performance data for the VNUS ... leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that causes the varicose veins afflicting ...

FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)

... (PPIs) have been shown to be beneficial for patients with gastroesophageal reflux disease (GERD). PPIs are generally well tolerated and PRILOSEC/LOSEC and ... treatment of heartburn and other symptoms associated with gastroesophageal reflux disease. PRILOSEC is also indicated for the short-term treatment (4 to 8 ...

It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer

... esophagus, a serious complication of chronic, severe gastroesophageal reflux disease (GERD). Barrett's esophagus has been recognized as a major risk ... anyone, even those who do not have obvious symptoms of gastroesophageal reflux disease. To learn more about Barrett's esophagus or to schedule an ...

Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons

... treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a uniform and controlled ablation effect, which removes the diseased tissue and ...

Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barrett's Esophagus

... treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a uniform and controlled ablation effect, which removes the diseased tissue and ...

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis

... dysphagia (problems swallowing), vomiting, stomach pain, chest pain, heartburn, loss of weight, and food impaction. Other symptoms may include reflux that does not respond to proton pump inhibitor therapy, failure to thrive, poor appetite, malnutrition and difficulty sleeping. The ...

Cephalon Signs Option Agreement to Acquire Ception Therapeutics

... is characterized by an accumulation of eosinophils in the esophagus in association with symptoms that frequently mimic severe gastro-esophageal reflux disease (GERD). Specifically, patients typically report symptoms that include difficulty feeding and failure to thrive in younger children, as well ...

Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System

... that Barrett's esophagus affects approximately six million European and US adults and is a complication of a disorder called gastroesophageal reflux disease or GERD. Once diagnosed, Barrett's can worsen over time, developing dysplasia and esophageal adenocarcinoma (cancer), as in this study. Once ...

Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use

... or bleeding, presence of H. pylori (a common bacteria that contributes to the development of stomach ulcers), dyspepsia or GERD (gastroesophageal reflux disease or "acid reflux") symptoms, as well as the simultaneous use of NSAIDs, anticoagulants and/or corticosteroids. The presence of several risk ...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... program is licensed to Bristol-Myers Squibb. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. Kosan recently agreed to be acquired by Bristol-Meyers Squibb. For additional information on Kosan Biosciences, ...

AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication

... Delayed-Release Capsules In adults, NEXIUM is approved for treating frequent, persistent heartburn and other symptoms associated with acid reflux disease as well as healing erosive esophagitis. Most erosions heal in four to eight weeks. Individual results may vary, and only a doctor can ...

Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination

... treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its flagship product, the HALO360 System, provides uniform and controlled therapy at a consistent depth, which can remove Barrett's ...

TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis

... results coupled with the overall healing results are encouraging for the potential of TAK-390MR in treating patients with gastroesophageal reflux disease." About TAK-390MR TAK-390MR, an enantiomer of lansoprazole, employs an innovative dual delayed release technology, which is designed to ...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

... trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com . This ...

Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome

... has also reported positive results from a Phase 2a clinical trial of its second product candidate, XP19986, in patients with gastroesophageal reflux disease. To learn more about XenoPort, please visit the web site at http://www.XenoPort.com . About GlaxoSmithKline GlaxoSmithKline is one of ...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

... 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com . This ...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

... trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com . This ...

Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children

... on the basis of an esophageal biopsy demonstrating the presence of significant numbers of eosinophils, clinical symptoms, and the absence of acid reflux or failure to respond to acid reduction therapy.(1) Allergic responses have been strongly implicated in the etiology of EE.(1) The overexpression ...

Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers

... and CEO of CSA Medical. "More than 6 million people in the U.S. have Barrett's esophagus, while 65 million people suffer from GastroEsophageal reflux Disease (GERD), also called "acid reflux" or "heartburn". Approximately 350,000 persons with GERD develop more dangerous lesions, while 15,000 ...

Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease

... and liver diseases including Pouchitis, Hepatic Encephalopathy, Irritable Bowel Syndrome and Proton Pump Inhibitor-resistant Gastroesophageal reflux Disease. Ocera Therapeutics has raised $26.5 million dollars in venture financing from Domain Associates, Sofinnova Ventures and Thomas, McNerney & ...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

... and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com . This press release ...

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

... and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan Biosciences, please visit the Company's website at http://www.kosan.com . This press release ...

Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

... ADX10059 in patients with gastro-esophageal reflux disease (GERD), a highly prevalent condition with ... relaxation of the sphincter muscle and causing reflux of stomach contents into the esophagus, ... of the lower esophageal sphincter, and prevents reflux of stomach contents into the esophagus. As ...

New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting

... pediatric patients with gastroesophageal reflux disease (GERD) during oral and poster sessions at ... and Improvement in Symptoms of Gastroesophageal reflux Disease (GERD) in 1- and 2-Year-Old Children ... Effect of Esomeprazole on Gastroesophageal reflux Measured by 24-hour pH- Impedance Monitoring in ...

Dynogen Reports Positive Results in Phase 1B GERD Study

... Phase 1b trial of DDP733 for gastroesophageal reflux disease (GERD). The study was designed ... primary endpoint of reduction in the number of reflux events and was safe and well tolerated. Dynogen ... high fat meal to induce gastroesophageal reflux. reflux events were measured by intraesophageal impedance ...

Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study

... - DDP733 reduces esophageal reflux - Waltham, Mass., June 7, 2007 – Dynogen ... primary endpoint of reduction in the number of reflux events and was safe and well tolerated. Dynogen ... high fat meal to induce gastroesophageal reflux. reflux events were measured by intraesophageal impedance ...

Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections

... ages three and five, Caucasians, and those with severe vesicoureteral reflux had the highest risk of recurrent UTI. Receiving a daily dose of ... is recommended in an attempt to prevent recurrent UTIs. Vesicoureteral reflux (VUR) occurs when urine in the bladder flows back into the ureters or ...